Ritonavir
- Generic Name
- Ritonavir
- Brand Names
- Kaletra, Norvir, Paxlovid, Viekira Pak, Ritonavir Mylan
- Drug Type
- Small Molecule
- Chemical Formula
- C37H48N6O5S2
- CAS Number
- 155213-67-5
- Unique Ingredient Identifier
- O3J8G9O825
- Background
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibi...
- Indication
Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection.
...
- Associated Conditions
- Chronic hepatitis C genotype 1a, Chronic hepatitis C genotype 1b, Human Immunodeficiency Virus Type 1 (HIV-1) Infection, Mild, moderate Novel Coronavirus Infectious Disease (COVID-19)
- Associated Therapies
- -
Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment
Phase 4
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2015-06-02
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Nova Scotia Health Authority
- Target Recruit Count
- 44
- Registration Number
- NCT02460133
HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-05-07
- Last Posted Date
- 2024-01-09
- Target Recruit Count
- 122
- Registration Number
- NCT02437110
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-04-30
- Last Posted Date
- 2023-03-03
- Lead Sponsor
- Eiger BioPharmaceuticals
- Target Recruit Count
- 55
- Registration Number
- NCT02430194
- Locations
- 🇹🇷
Ankara University Medical School, Ankara, Turkey
Lonafarnib With and Without Ritonavir in HDV (LOWR-1)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-04-30
- Last Posted Date
- 2022-11-29
- Lead Sponsor
- Eiger BioPharmaceuticals
- Target Recruit Count
- 21
- Registration Number
- NCT02430181
- Locations
- 🇹🇷
Ankara University Medical School, Ankara, Turkey
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of RO6889678 and the Combination of RO6889678 With Ritonavir in Healthy Participants
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2014-12-22
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 100
- Registration Number
- NCT02321384
- Locations
- 🇳🇱
Centre For Human Drug Research; Research, Leiden, Netherlands
A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2017-05-09
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 24
- Registration Number
- NCT02289495
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
A Single Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2014-11-13
- Last Posted Date
- 2017-05-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20
- Registration Number
- NCT02289482
- Locations
- 🇺🇸
GSK Investigational Site, Baltimore, Maryland, United States
Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-10-27
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 769
- Registration Number
- NCT02275780
Pharmacokinetics (PK) of Tipranavir/Ritonavir, Ribavirin, Pegylated Interferon (Peg INF) in Hepatitis C (HCV) Subjects With Mild Hepatic Impairment and in HCV, Hepatitis B (HBV), Hepatitis D Infected Subjects or Alcoholic Cirrhosis With Moderate Hepatic Impairment
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT02259855
Study of New Tablet Formulations and Suspension Formulation Compared to Current (1B) Formulation of BILR 355 BS in Healthy Male Volunteer Subjects
Phase 1
Completed
- Conditions
- Interventions
- Drug: BILR 355 BS /1B, current low dose formulationDrug: BILR 355 BS /1B, current high dose formulationDrug: BILR 355 BS - Jet Milled (JM) + Sodium Dodecyl Sulfate (SDS) formulationDrug: BILR 355 BS - Suspension low doseDrug: RitonavirDrug: BILR 355 BS - Hammer Milled (HM) + Sodium Dodecyl Sulfate (SDS) formulationDrug: BILR 355 BS - Suspension high dose
- First Posted Date
- 2014-10-09
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 88
- Registration Number
- NCT02259868
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath